These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 36669559)
1. Bacteriophage therapy for human musculoskeletal and skin/soft tissue infections. Metsemakers WJ; Onsea J; Moriarty TF; Pruidze N; Nadareishvili L; Dadiani M; Kutateladze M Clin Microbiol Infect; 2023 Jun; 29(6):695-701. PubMed ID: 36669559 [TBL] [Abstract][Full Text] [Related]
2. Bacteriophage Application for Difficult-to-treat Musculoskeletal Infections: Development of a Standardized Multidisciplinary Treatment Protocol. Onsea J; Soentjens P; Djebara S; Merabishvili M; Depypere M; Spriet I; De Munter P; Debaveye Y; Nijs S; Vanderschot P; Wagemans J; Pirnay JP; Lavigne R; Metsemakers WJ Viruses; 2019 Sep; 11(10):. PubMed ID: 31548497 [TBL] [Abstract][Full Text] [Related]
3. Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going? Luong T; Salabarria AC; Roach DR Clin Ther; 2020 Sep; 42(9):1659-1680. PubMed ID: 32883528 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics/pharmacodynamics of phage therapy: a major hurdle to clinical translation. Nang SC; Lin YW; Petrovic Fabijan A; Chang RYK; Rao GG; Iredell J; Chan HK; Li J Clin Microbiol Infect; 2023 Jun; 29(6):702-709. PubMed ID: 36736661 [TBL] [Abstract][Full Text] [Related]
7. Towards Inhaled Phage Therapy in Western Europe. Wienhold SM; Lienau J; Witzenrath M Viruses; 2019 Mar; 11(3):. PubMed ID: 30909579 [TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
9. Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review. Kakasis A; Panitsa G Int J Antimicrob Agents; 2019 Jan; 53(1):16-21. PubMed ID: 30236954 [TBL] [Abstract][Full Text] [Related]
10. Bacteriophage as an antibacterial agent: a patent perspective. Pathak-Vaidya P; Sharma S; Telang M Future Microbiol; 2021 Nov; 16():1327-1339. PubMed ID: 34755539 [TBL] [Abstract][Full Text] [Related]
12. Bacteriophage therapy for challenging bacterial infections: achievements, limitations and prospects for future clinical use by veterinary dermatologists. Squires RA Vet Dermatol; 2021 Dec; 32(6):587-e158. PubMed ID: 33870572 [TBL] [Abstract][Full Text] [Related]
14. Bacteriophages as Therapeutic and Prophylactic Means: Summary of the Soviet and Post Soviet Experiences. Chanishvili N Curr Drug Deliv; 2016; 13(3):309-23. PubMed ID: 27090515 [TBL] [Abstract][Full Text] [Related]
15. Current Clinical Landscape and Global Potential of Bacteriophage Therapy. Hitchcock NM; Devequi Gomes Nunes D; Shiach J; Valeria Saraiva Hodel K; Dantas Viana Barbosa J; Alencar Pereira Rodrigues L; Coler BS; Botelho Pereira Soares M; Badaró R Viruses; 2023 Apr; 15(4):. PubMed ID: 37113000 [TBL] [Abstract][Full Text] [Related]
16. Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. Verbeken G; Pirnay JP; De Vos D; Jennes S; Zizi M; Lavigne R; Casteels M; Huys I Arch Immunol Ther Exp (Warsz); 2012 Jun; 60(3):161-72. PubMed ID: 22527355 [TBL] [Abstract][Full Text] [Related]
17. Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. Pirnay JP; Djebara S; Steurs G; Griselain J; Cochez C; De Soir S; Glonti T; Spiessens A; Vanden Berghe E; Green S; Wagemans J; Lood C; Schrevens E; Chanishvili N; Kutateladze M; de Jode M; Ceyssens PJ; Draye JP; Verbeken G; De Vos D; Rose T; Onsea J; Van Nieuwenhuyse B; ; ; Soentjens P; Lavigne R; Merabishvili M Nat Microbiol; 2024 Jun; 9(6):1434-1453. PubMed ID: 38834776 [TBL] [Abstract][Full Text] [Related]
18. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. Malik DJ; Sokolov IJ; Vinner GK; Mancuso F; Cinquerrui S; Vladisavljevic GT; Clokie MRJ; Garton NJ; Stapley AGF; Kirpichnikova A Adv Colloid Interface Sci; 2017 Nov; 249():100-133. PubMed ID: 28688779 [TBL] [Abstract][Full Text] [Related]
19. Bacteriophage therapy for management of bacterial infections in veterinary practice: what was once old is new again. Squires RA N Z Vet J; 2018 Sep; 66(5):229-235. PubMed ID: 29925297 [TBL] [Abstract][Full Text] [Related]
20. [Susceptibilities of multidrug-resistant pathogens responsible for complicated skin and soft tissue infections to standard bacteriophage cocktails]. Gündoğdu A; Kılıç H; Ulu Kılıç A; Kutateladze M Mikrobiyol Bul; 2016 Apr; 50(2):215-23. PubMed ID: 27175494 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]